Search

Catriona H Jamieson

from La Jolla, CA
Age ~59
Get Report
Also known as:
Catriona Helen Jamieson, Catriona Helen Macleod Jamieson, Catriona H Jamison, Catriona M Jamieson
Phone and address:
7400 Hillside Dr, La Jolla, CA 92037
Related to:
Nicholas A Cacalano
Connected to:
Amy Jamieson, 47Anne M Jamieson, 71Ben T Jamieson, 37Bethany E Jamieson, 34Bradley B Jamieson, 41Carly Jamieson, 52Carol L Jamieson, 71Cheryl Jamieson, 66Corey R Jamieson, 48Dale R Jamieson, 52

Catriona Jamieson Phones & Addresses

  • 7400 Hillside Dr, La Jolla, CA 92037
  • 6682 Avenida Mirola, La Jolla, CA 92037 (858) 454-2506
  • 425 Homer Ave, Palo Alto, CA 94301 (650) 323-4108

Work

Company: UCSD Morris Cancer Center Address: 3855 Health Sciences Dr Suite 1102, La Jolla, CA 92093 Phones: (858) 822-6100

Education

School / High School: University Of British Columbia Faculty Of Medicine 1995

Languages

English • Chinese • Russian • Spanish

Awards

Healthgrades Honor Roll

Ranks

Certificate: Hematology, 2001

Industries

Medical Practice

Specialities

Hematology

Professional Records

Medicine Doctors

Catriona Jamieson Photo 1

Dr. Catriona Jamieson, La Jolla CA - MD (Doctor of Medicine)

View page
Specialties:
Hematology
Address:
UCSD Morris Cancer Center
3855 Health Sciences Dr Suite 1102, La Jolla, CA 92093
(858) 822-6100 (Phone)
Certifications:
Hematology, 2001
Internal Medicine, 1998
Awards:
Healthgrades Honor Roll
Languages:
English
Chinese
Russian
Spanish
Education:
Medical School
University Of British Columbia Faculty Of Medicine
Graduated: 1995
Catriona Jamieson Photo 2

Catriona Jamieson

View page
Specialties:
Hematology/Oncology
Work:
UCSD Medical GroupUCSD Moores Cancer Center
3855 Health Sciences Dr, La Jolla, CA 92093
(858) 822-6100 (phone), (858) 246-1847 (fax)

UCSD Medical GroupUCSD Medical Center Hematology Oncology
3855 Health Sciences Dr, La Jolla, CA 92093
(858) 822-6100 (phone), (858) 822-6844 (fax)
Education:
Medical School
Univ of British Columbia, Fac of Med, Vancouver, Bc, Canada
Graduated: 1995
Procedures:
Bone Marrow Biopsy
Conditions:
Anemia
Leukemia
Hemophilia A or B
Malignant Neoplasm of Female Breast
Multiple Myeloma
Languages:
English
Description:
Dr. Jamieson graduated from the Univ of British Columbia, Fac of Med, Vancouver, Bc, Canada in 1995. She works in La Jolla, CA and 1 other location and specializes in Hematology/Oncology. Dr. Jamieson is affiliated with UCSD Medical Center and UCSD Thornton Hospital.
Catriona Jamieson Photo 3

Catriona Jamieson, La Jolla CA

View page
Specialties:
Internal Medicine
Hematology
Hematology & Oncology
Medical Oncology
Work:
Urgentcare San Diego Moores Cancer Center
3855 Health Sciences Dr, La Jolla, CA 92093
Education:
University Of British Columbia Faculty Of Medicine (1995)
Catriona Jamieson Photo 4

Catriona Jamieson, La Jolla CA

View page
Specialties:
Internist
Address:
3855 Health Sciences Dr, La Jolla, CA 92093

Resumes

Resumes

Catriona Jamieson Photo 5

Catriona Jamieson

View page
Location:
Greater San Diego Area
Industry:
Medical Practice

Business Records

Name / Title
Company / Classification
Phones & Addresses
Catriona Jamieson
Hematology
Moores Ucsd Cancer Center
College/University · Oncology · Surgeons · Radiology · Plastic Surgery · Internist · Urologist · Obgyn
3855 Health Sciences Dr, La Jolla, CA 92093
(858) 822-6146

Publications

Us Patents

Wnt Signaling Inhibitors, And Methods For Making And Using Them

View page
US Patent:
8304408, Nov 6, 2012
Filed:
May 15, 2008
Appl. No.:
12/600996
Inventors:
Wolfgang Wrasidlo - La Jolla CA, US
Catriona H. Jamieson - La Jolla CA, US
Dennis Carson - La Jolla CA, US
Tadeusz F. Molinski - La Jolla CA, US
Desheng Lu - La Jolla CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/35
A61P 35/02
US Classification:
51421206, 51421207
Abstract:
The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e. g. , in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.

Methods Of Identifying And Isolating Stem Cells And Cancer Stem Cells

View page
US Patent:
20040018531, Jan 29, 2004
Filed:
May 30, 2003
Appl. No.:
10/449795
Inventors:
Catriona Jamieson - Palo Alto CA, US
Laurie Ailles - Stanford CA, US
Tannishtha Reya - Mountain View CA, US
Irving Weissman - Redwood City CA, US
International Classification:
C12Q001/68
G01N033/53
G01N033/567
C12N005/08
US Classification:
435/006000, 435/007200, 435/372000
Abstract:
Methods and compositions are provided for the identification of stem cells and cancer stem cells. -catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at -catenin, or members of the -catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized -catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.

Methods For Diagnosing And Evaluating Treatment Of Blood Disorders

View page
US Patent:
20070111238, May 17, 2007
Filed:
Sep 27, 2006
Appl. No.:
11/528890
Inventors:
Catriona Jamieson - Palo Alto CA, US
Irving Weissman - Stanford CA, US
International Classification:
C12Q 1/68
G01N 33/574
US Classification:
435006000, 435007230
Abstract:
Methods, systems and kits are provided for the clinical staging of blood disorders including myelodysplastic syndrome, myeloproliferative diseases and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets. Additional functional, genetic, gene expression, proteomic or other molecular analyses of the hematopoietic stem and progenitor cells from the patients can also be employed in the staging methods of the invention.

Methods Of Identifying And Isolating Stem Cells And Cancer Stem Cells

View page
US Patent:
20070238127, Oct 11, 2007
Filed:
May 2, 2007
Appl. No.:
11/799817
Inventors:
Catriona Jamieson - La Jolla CA, US
Laurie Ailles - Palo Alto CA, US
Tannishtha Reya - Chapel Hill NC, US
Irving Weissman - Stanford CA, US
International Classification:
C12Q 1/02
C12N 15/09
C12Q 1/68
US Classification:
435006000, 435029000, 435455000
Abstract:
Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.

Compositions And Methods For Determining Cancer Stem Cell Self-Renewal Potential

View page
US Patent:
20110059448, Mar 10, 2011
Filed:
Jun 23, 2010
Appl. No.:
12/821738
Inventors:
Catriona H. JAMIESON - La Jolla CA, US
Annelie SCHAIRER - Escondido CA, US
Ifat GERON - San Diego CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C12Q 1/68
C12Q 1/02
US Classification:
435 6, 435 29
Abstract:
In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes.

Anticancer And Antifungal Splice Modulators

View page
US Patent:
20220227742, Jul 21, 2022
Filed:
Jan 12, 2022
Appl. No.:
17/574100
Inventors:
- Oakland CA, US
Warren C. Chan - La Jolla CA, US
James J. La Clair - La Jolla CA, US
Kelsey A. Trieger - La Jolla CA, US
Catriona Jamieson - La Jolla CA, US
International Classification:
C07D 407/12
Abstract:
Provided herein, inter alia, are splice modulator compounds. The compounds include optically pure, stereospecific analogs of FD-895. The methods provided herein allow, for example, for scalable preparation of said compounds, and further allow, for example, use of said compounds for inhibiting spliceosome activity.
Control profile
Catriona H Jamieson from La Jolla, CA, age ~59 Get Report